DORM:NASDAQDorman Products, Inc. Analysis
Data as of 2026-09-01 - not real-time
$127.04
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Dorman Products, Inc. trades at $127.04, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Across the trailing 30 sessions it lost 7.6%. Relative strength is 40.6 — neutral — and the MACD signal is bearish. The recent range runs from support at $125.54 up to resistance at $147.56.
Valuation screens as undervalued, on a P/E of 17.6 with no clean sector comparison available. Consensus targets land 27.8% above where the shares trade now.
The composite risk read is 7/10, putting it in elevated territory. With 30-day volatility of 58.0%, a beta of 0.76 and a maximum drawdown of 39.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 6 out of 10.
Valuation screens as undervalued, on a P/E of 17.6 with no clean sector comparison available. Consensus targets land 27.8% above where the shares trade now.
The composite risk read is 7/10, putting it in elevated territory. With 30-day volatility of 58.0%, a beta of 0.76 and a maximum drawdown of 39.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 6 out of 10.
Top Market Events
Dorman Products, Inc. reported past second-quarter 2026 results with sales of US$544.6 million and net income of...Dorman Products DORM might move higher on growing optimism about its earnings prospects, which is reflected by its...Highlights All comparisons are to the prior year period unless otherwise noted : Net sales of $544.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 4/10
Key Factors
- Trading above the 200-day average of 124.00
- MACD momentum is negative
- 30-day price change of -7.6%
Medium Term
1–3 yearsPositive
Model confidence: 5/10
Key Factors
- Trading above the 200-day average of 124.00
- Analyst targets imply +27.8% versus the current price
- 30-day volatility of 58.0%
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Analyst targets imply +27.8% versus the current price
- P/E ratio of 17.6
- Return on equity of 15.0%
Key Metrics & Analysis
Financial Health
Revenue Growth0.70%
Profit Margin10.18%
P/E Ratio17.6
ROE15.05%
ROA9.17%
Debt/Equity34.87
P/B Ratio2.5
Op. Cash Flow$250.2M
Free Cash Flow$144.0M
Technical Analysis
TrendNeutral
RSI40.6
Support$125.54
Resistance$147.56
MA 20$132.90
MA 50$135.20
MA 200$124.00
MACDBearish
VolumeDecreasing
Fear & Greed Index92.8
Valuation
Fair Value$50.31
Target Price$162.38
Upside/Downside27.81%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.76
Volatility57.97%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.